Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer

Overview of attention for article published in Cancer Management and Research, November 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 19 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 906 followers.

New article: Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer https://t.co/jXQhBZEnD1 #breastcancer #oncology https://t.co/ZXSl52KwCY

Reply Repost Favourite